Status:
COMPLETED
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Parkinson Disease
Dyskinesia, Drug-Induced
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The purpose of this study is to generate long-term safety, tolerability and efficacy data for AFQ056 in patients who have participated in and completed any AFQ056 phase II study in PD-LID (Parkinson's...
Eligibility Criteria
Inclusion
- Outpatients with Parkinson's disease (PD), treated with L-Dopa, experiencing dyskinesias who have been eligible for, participated in and completed an AFQ056 phase II core study.
Exclusion
- Surgical treatment for PD
- Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated)
- Advanced, severe or unstable disease (other than PD) that may interfere with the study outcome evaluations
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT01173731
Start Date
October 1 2010
End Date
October 1 2013
Last Update
December 23 2020
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Sunnyvale, California, United States, 94089
2
Novartis Investigative Site
Englewood, Colorado, United States, 80113
3
Novartis Investigative Site
Indianapolis, Indiana, United States, 46202
4
Novartis Investigative Site
Heidelberg, Victoria, Australia, 3081